Page 29 - GTM-2-2

Global Translational Medicine Use of cardio biomarker in diagnosis of AMI

peptides. N Engl J Med, 339: 321–328. https://doi.org/10.1186/s12872-016-0250-2
https://doi.org/10.1056/NEJM199807303390507 50. Xie S, Lu L, Liu L, 2019, Growth differentiation factor-15
41. De Ames JA, Morrow DA, Bentley JH, et al., 2001, The and the risk of cardiovascular diseases and all-cause
prognostic value of B-type natriuretic peptide in patients mortality: A meta-analysis of prospective studies. Clin
with acute coronary syndromes. N Engl J Med, 345: Cardiol, 42: 513–523.
1014–1021. https://doi.org/10.1002/clc.23159
https://doi.org/10.1056/nejmoa011053 51. Daniels LB, Clopton P, Laughlin GA, et al., 2011, Growth-
42. Vasile VC, Babuin L, Giannitsis E, et al., 2008, Relationship differentiation factor-15 is a robust, independent predictor
of MRI-determined infarct size and cTnI measurements of 11-year mortality risk in community-dwelling older
in patients with ST-elevation myocardial infarction. Clin adults: The Rancho Bernardo Study. Circulation, 123:
Chem, 54: 617–619. 2101–2110.
https://doi.org/10.1373/clinchem.2007.095604 https://doi.org/10.1161/circulationaha.110.979740
43. Richards AM, Nicholls MG, Yandle TG, et al., 1998, 52. Bodde MC, Hermans MPJ, van der Laarse A, et al., 2019,
Plasma N-terminal pro-brain natriuretic peptide and Growth differentiation factor-15 levels at admission provide
adrenomedullin: New neurohormonal predictors of left incremental prognostic information on all-cause long-term
ventricular function and prognosis after myocardial mortality in ST-segment elevation myocardial infarction
infarction. Circulation, 97: 1921–1929. patients treated with primary percutaneous coronary
intervention. Cardiol Ther, 8: 29–41.
https://doi.org/10.1161/01.cir.97.19.1921
https://doi.org/10.1007/s40119-019-0127-4
44. Squire IB, O’Brien RJ, Demme B, et al., 2004, N-terminal
pro-atrial natriuretic peptide (N-ANP) and N-terminal 53. Wang XY, Zhang F, Zhang C, et al., 2020, The biomarkers for
pro-B-type natriuretic peptide (N-BNP) in the prediction acute myocardial infarction and heart failure. Biomed Res
of death and heart failure in unselected patients following Int, 2020: 2018035.
acute myocardial infarction. Clin Sci, 107: 309–316. https://doi.org/10.1155/2020/2018035
https://doi.org/10.1042/CS20040087 54. Sanada S, Hakuno D, Higgins LJ, et al., 2007, IL-33 and
45. Morgenthaler NG, Struck J, Thomas B, et al., 2004, ST2 comprise a critical biomechanically induced and
Immunoluminometric assay for the midregion of pro- cardioprotective signaling system. J Clin Invest, 117:
atrial natriuretic peptide in human plasma. Clin Chem, 50: 1538–1549.
234–236. https://doi.org/10.1172/JCI30634
https://doi.org/10.1373/clinchem.2003.021204 55. Seki K, Sanada S, Kudinova AY, et al., 2009, Interleukin-33
46. Khan SQ, Dhillon O, Kelly D, et al., 2008, Plasma N-terminal prevents apoptosis and improves survival after experimental
B-type natriuretic Peptide as an indicator of long-term myocardial infarction through ST2 signaling. Circ Heart
survival after acute myocardial infarction: Comparison Fail, 2: 684–691.
with plasma midregional pro-atrial natriuretic peptide. https://doi.org/10.1161/circheartfailure.109.873240
The LAMP (Leicester Acute Myocardial Infarction Peptide)
study. J Am Coll Cardiol, 51: 1857–1864. 56. Díez J, 2008, Serum soluble ST2 as a biochemical marker
of acute heart failure. Future areas of research. J Am Coll
https://doi.org/10.1016/j.jacc.2008.01.041 Cardiol, 52: 1466–1467.
47. Ho JE, Mahajan A, Chen MH, et al., 2012, Clinical and https://doi.org/10.1016/j.jacc.2008.07.045
genetic correlates of growth differentiation factor 15 in the
community. Clin Chem, 58: 1582–1591. 57. Zhou L, Liu Y, Lu Y, et al., 2022, Recent advances in the
immunoassays based on nanozymes. Biosensors (Basel),
https://doi.org/10.1373/clinchem.2012.190322
12: 1119.
48. Schopfer DW, Ku IA, Regan M, et al., 2014, Growth https://doi.org/10.3390/bios12121119
differentiation factor 15 and cardiovascular events in
patients with stable ischemic heart disease (The Heart and 58. Yang J, Wang X, Sun Y, et al., 2023, Recent advances in
Soul Study). Am Heart J, 167: 186–192.e1. colorimetric sensors based on gold nanoparticles for
pathogen detection. Biosensors (Basel), 13: 29.
https://doi.org/10.1016/j.ahj.2013.09.013
https://doi.org/10.3390/bios13010029
49. Zhang S, Dai D, Wang X, et al., 2016, Growth differentiation
factor-15 predicts the prognoses of patients with acute 59. Choi DH, Lee SK, Oh YK, et al., 2010, A dual gold
coronary syndrome: A meta-analysis. BMC Cardiovasc nanoparticle conjugate-based lateral flow assay (LFA)
Disord, 16: 82. method for the analysis of troponin I. Biosens Bioelectron,

Volume 2 Issue 2 (2023) 11 https://doi.org/10.36922/gtm.0403